These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24769656)

  • 1. Posttreatment assessment of women at risk of developing high-grade cervical disease: proposal for new guidelines based on data from the Netherlands.
    Uijterwaal MH; Kocken M; Berkhof J; Bekkers RL; Verheijen RH; Helmerhorst TJ; Meijer CJ
    J Low Genit Tract Dis; 2014 Oct; 18(4):338-43. PubMed ID: 24769656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
    Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
    J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical performance of the aptima HPV assay in 4196 women with positive high-risk HPV and ASC-US cytology: A large women hospital experience.
    Wang T; Pradhan D; Zhang H; Matsko J; Zhao C
    Diagn Cytopathol; 2021 Jan; 49(1):5-10. PubMed ID: 32857920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?
    van der Marel J; Berkhof J; Ordi J; Torné A; Del Pino M; van Baars R; Schiffman M; Wentzensen N; Jenkins D; Quint WG
    Am J Surg Pathol; 2015 Apr; 39(4):496-504. PubMed ID: 25353286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
    Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
    Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
    Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
    Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5-year risk of recurrence of grade 2/3 cervical intraepithelial neoplasia after treatment in a population screening programme by human papillomavirus status: A cohort study in central Italy.
    Visioli CB; Iossa A; Gorini G; Mantellini P; Lelli L; Auzzi N; Pierro CD; Carozzi FM; Zappa M
    J Med Screen; 2023 Dec; 30(4):191-200. PubMed ID: 37229655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
    Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
    Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
    JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of DNA and RNA based HPV tests for test of cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study.
    Bhatia R; Graham C; Elasifer H; Asodaria P; Moncur S; Wilson A; Palmer T; Cuschieri K
    J Clin Virol; 2022 Jun; 150-151():105165. PubMed ID: 35487094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
    Schuurman TN; Schaafsma M; To KH; Verhoef VMJ; Sikorska K; Siebers AG; Wenzel HHB; Bleeker MCG; Roes EM; Zweemer RP; de Vos van Steenwijk PJ; Yigit R; Beltman JJ; Zusterzeel PLM; Lok CAR; Bekkers RLM; Mom CH; van Trommel NE
    Lancet Oncol; 2023 Dec; 24(12):1349-1358. PubMed ID: 37952541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.